Phase II study of sunitinib in men with advanced prostate cancer

Background: This study explored the efficacy and tolerability of sunitinib, an inhibitor of tyrosine kinase receptors, in men with castration-resistant prostate cancer (CRPC). Methods: Men with no prior chemotherapy (group A) and men with docetaxel (Taxotere)-resistant prostate cancer (group B) were...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Dror Michaelson, M., Regan, M. M., Oh, W. K., Kaufman, D. S., Olivier, K., Michaelson, S. Z., Spicer, B., Gurski, C., Kantoff, P. W., Smith, M. R.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2009
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2674960/
https://ncbi.nlm.nih.gov/pubmed/19403935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdp111
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items